The elusive goal of selecting the right number and type of genes for breast and ovarian cancer pharmacodiagnostics can be achieved in future by application of pathology-supported genetic testing extending from BRCA1/2 founder variant screening to multigene panel testing complemented by WES/WGS in genetically uninformative cases. The gene discussed is BRCA1; the disease is ovarian carcinoma.